Rock Springs Capital NUVB Position
Active7-Fund ConvergenceRock Springs Capital held their position in Nuvation Bio Inc. (NUVB) in Q4 2025, holding $44K worth of shares across 134,028 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
NUVB is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for NUV-1511 in 349 days (Mar 31, 2027), making the timing of Rock Springs's position particularly relevant.
Short interest stands at 22.6% of float with 9.6 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Full company profile →Short Interest
22.6%
9.6 days to cover
Rock Springs Capital NUVB Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 134,028 | — | $44K |
| Q3 2025 | Held | 134,028 | — | $27K |
| Q2 2025 | Held | 134,028 | — | $36K |
| Q1 2025 | Held | 134,028 | — | $32K |
| Q4 2024 | Held | 134,028 | — | $31K |
| Q3 2024 | Held | 134,028 | — | $13K |
| Q2 2024 | Held | 134,028 | — | $21K |
| Q1 2024 | Held | 134,028 | — | $41K |
| Q4 2023 | Held | 134,028 | — | $8K |
| Q3 2023 | Held | 134,028 | — | $13K |
| Q2 2023 | Held | 134,028 | — | $22K |
| Q1 2023 | New | 134,028 | +134,028 | $16K |
Frequently Asked Questions
Does Rock Springs Capital own NUVB?
Yes. As of Q4 2025, Rock Springs Capital holds 134,028 shares of Nuvation Bio Inc. (NUVB) valued at $44K. This data comes from their SEC 13F filing.
How many hedge funds own NUVB?
7 specialist biotech hedge funds currently hold NUVB, including EcoR1 Capital, Tang Capital Management, Redmile Group and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy NUVB?
Rock Springs Capital's position in NUVB was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's NUVB position increasing or decreasing?
Rock Springs Capital held their NUVB position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NUVBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →